Press release -
Athera allowed US composition of matter patents for therapeutic antibodies
Stockholm Sept 25, 2017
Athera Biotechnologies AB today announced that two composition of matter patents have been allowed for antibodies with binding to phosphorylcholine, PC. The PC target is part of modified phospholipids and has been characterized as an active driver of vascular inflammation. The therapeutic antibodies covered by the patents are designed to target and block PC and thereby reduce inflammation.
“Our lead candidate PC-mAb is covered by these patents and we are thrilled with the progress of the project through early clinical development and towards the upcoming Phase 2a study” says Carina Schmidt, CEO of Athera.
The clinical stage fully human antibody PC-mAb from Athera is designed to mimic the anti-inflammatory role of endogenous antibodies against PC and act to support the immune response to vascular inflammation challenges and thereby reduce the risk for complications in immunovascular diseases.
For more information, contact: Carina Schmidt, CEO, Athera Biotechnologies AB
Phone: +46 (0)76 1938 190, email: c.schmidt@athera.se
Topics
- Business enterprise, General
Categories
- clinical study
- intellectual property
- composition of matter
- patent
- clinical
- cardiovascular disease
- athera biotechnologies
- target
- phopsholipids
- therapeutic antibodies
- phosphorylcholine
- therapeutic antibody
- läkemedel
- immunovascular disease
- hjärtkärlsjukdom
- athera
About Athera Biotechnologies AB
The mission of Athera is to address the large unmet need for anti-inflammatory therapeutics in the treatment of immunovascular disease. Athera´s focus is on PC-mAb, a clinical stage biopharmaceutical program with block-buster potential. Development of PC-mAb has been co-funded by EU FP7 in the CARDIMMUN project. Major shareholders are Industrifonden, The Foundation for Baltic and East European Studies (Östersjöstiftelsen) and Linc AB.For more information: www.athera.se
